上海萊士(002252.SZ):未來將繼續按照戰略合作協議約定推進與基立福的合作
格隆匯6月7日丨上海萊士(002252.SZ)於2023年6月6日下午13:00-14:00召開網絡會議,交流互動環節中,就“基立福在公司今後的發展中將有什麼具體的舉措?”,公司回覆稱,根據公司與基立福簽訂的《排他性戰略合作總協議》約定,公司與基立福將在生產質量規範、知識產權、技術研發、管理經驗、銷售渠道、工程和協作服務等領域展開深入合作。公司已陸續與基立福就質量管理、代理進口人血白蛋白、代理GDS相關產品等方面展開合作,上述事項對公司經營產生積極影響。未來,公司也將繼續按照戰略合作協議約定推進與基立福的合作,並按規定進行信息披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.